Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Suspended 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1Neoplasms 1

Interventions

E 7107 2Carboplatin 2palbociclib 1gedatolisib 1eniluracil 1dabrafenib 1abarelix 1Topotecan 1Standard of Care 1Radionuclide Imaging 1Radiofrequency Ablation 1Practice Guidelines as Topic 1Positron-Emission Tomography 1Passive Cutaneous Anaphylaxis 1Paclitaxel 1NUC-1031 1Morphine 1Methadone 1Maltose 1Magnetic Resonance Spectroscopy 1Magnetic Resonance Imaging 1KB004 1Injections 1Infusions, Parenteral 1Hyperthermic Intraperitoneal Chemotherapy 1Hydromorphone 1Gemcitabine 1Fluorodeoxyglucose F18 1Flucytosine 1Etoposide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × Neoplasms × abarelix × Clear all
NCT00103623 2006-09-19

The Plenaxis® Experience Study

PRAECIS Pharmaceuticals Inc.

Phase 4 Suspended
2,000 enrolled
Genitourinary

Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡